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Abstract: The liver plays a vital role in biotransforming and extricating xenobiotics and is 
thus prone to their toxicities. Short-term administration of carbon tetrachloride (CCl
4
) causes 
hepatic inflammation by enhancing cellular reactive oxygen species (ROS) level, promoting 
mitochondrial dysfunction, and inducing cellular apoptosis. Curcumin is well accepted for its 
antioxidative and anti-inflammatory properties and can be considered as an effective therapeu-
tic agent against hepatotoxicity. However, its therapeutic efficacy is compromised due to its 
insolubility in water. Vesicular delivery of curcumin can address this limitation and thereby 
enhance its effectiveness. In this study, it was observed that both liposomal and nanoparticu-
lated formulations of curcumin could increase its efficacy significantly against hepatotoxicity 
by preventing cellular oxidative stress. However, the best protection could be obtained through 
the polymeric nanoparticle-mediated delivery of curcumin. Mitochondria have a pivotal role in 
ROS homeostasis and cell survivability. Along with the maintenance of cellular ROS levels, 
nanoparticulated curcumin also significantly (P,0.0001) increased cellular antioxidant enzymes, 
averted excessive mitochondrial destruction, and prevented total liver damage in CCl
4
-treated 
rats. The therapy not only prevented cells from oxidative damage but also arrested the intrinsic 
apoptotic pathway. In addition, it also decreased the fatty changes in hepatocytes, centrizonal 
necrosis, and portal inflammation evident from the histopathological analysis. To conclude, 
curcumin-loaded polymeric nanoparticles are more effective in comparison to liposomal cur-
cumin in preventing CCl
4
-induced oxidative stress–mediated hepatocellular damage and thereby 
can be considered as an effective therapeutic strategy.
Keywords: reactive oxygen species, mitochondria, apoptosis, antioxidants, histopathology, 
Western blot
Introduction
Hepatotoxicity, harmful liver damage, is generally induced by different toxic chemi-
cals like alcohol, carbon tetrachloride (CCl
4
), aspirin, arsenic, diethylnitrosamine, etc. 
The liver plays a pivotal role in biotransforming and clearing these chemicals, and 
thus becomes susceptible to their toxicities. There are four stages of liver damage – 
inflammation, fibrosis, cirrhosis, and hepatocellular carcinoma. Short-term administra-
tion of CCl
4
 causes hepatic injury, centrilobular necrosis, steatosis, and inflammation.1 
Since human liver metabolizes CCl
4
 like that of rodents, CCl
4
-induced liver injury in 
rats can be an appropriate model for chemical-induced liver injury. The biotransforma-
tion of CCl
4
 takes place in liver, mainly catalyzed by different isotypes of cytochrome 
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P450 such as CYP2E1, CYP2B1, CYP2B2, and CYP3A. In 
humans, CYP2E1 metabolizes at environmentally relevant 
concentrations, but, at higher concentrations, CYP3A makes 
a notable contribution in the breakdown of CCl
4
. Breakdown 
of CCl
4
 produces trichloromethyl (CCl
3
*) and trichlorom-
ethyl peroxy (CCl
3
OO*) radicals. These highly reactive 
radicals preferentially bind with membrane phospholipids of 
different subcellular organelles like endoplasmic reticulum, 
mitochondria, and golgi apparatus of hepatocytes and cause 
lipid peroxidation and disruption of intracellular calcium 
homeostasis, resulting in the production of other reactive 
oxygen species (ROS).2,3 Mitochondria, the powerhouse of 
the cell, function as the principal source of ROS, which in 
turn damages mitochondria by forming lipohydroperoxide in 
mitochondrial membrane. This damage of the mitochondrial 
membrane causes opening of mitochondria permeability 
transition pores, disruption of mitochondrial membrane 
potential, and hindrance in normal electron transport chain 
and oxidative phosphorylation. These alterations in turn 
accelerate the oxidative stress in the hepatocytes. Further-
more, the extensive mitochondrial damage releases cyto-
chrome c from mitochondrial membrane, which activates 
the caspase-mediated apoptotic death as well as cellular 
necrosis.
Curcumin (Cur) [diferuloylmethane] is a polyphenolic 
compound obtained from the rhizomes of Curcuma longa. 
Over the past few decades, extensive studies have been car-
ried out to explore different pharmacological effects of this 
polyphenol, which demonstrates excellent antioxidant, anti-
inflammatory, and anticarcinogenic properties.4–7 Despite 
having multiple medicinal benefits, poor gastrointestinal 
(GI) absorption and lower oral bioavailability of this partially 
water-soluble compound restrict its use for effective therapy.8 
Recent evidences show that heat-treated curcumin and its dif-
ferent water-soluble analogs can address the issue of stability 
and solubility in aqueous environment.9,10 However, the best 
bioavailability can be achieved through various drug delivery 
vehicles like nanoparticles, liposomes, micelles, etc, which 
have shown promising results by improving circulation time, 
increasing cellular permeability, and shielding the drug from 
metabolic degradation.11
Among the different drug delivery vehicles, liposomes 
and polymeric nanoparticles are considered the most ben-
eficial for their high entrapment efficacy for both hydropho-
bic and hydrophilic substances and sustained and precise 
drug targeting.12 Recently, the polymeric nanoparticles 
have emerged as an attractive alternative to liposomes. 
The versatility of particulate technologies has enabled the 
use of polymeric nanoparticle-based drug delivery systems 
as they have many different advantages such as lower 
particle size, desired pharmacokinetic profile, improved 
bioavailability, and oral route of administration. Among 
the different drug delivery systems available in the market, 
biodegradable polymer poly(d,l-lactide-co-glycolide) 
(PLGA) is most commonly used because of its excellent 
biocompatibility.13
The aim of this study was to formulate curcumin-loaded 
liposomal and polymeric nanoparticulated formulations to 
overcome its solubility issue and improve the therapeutic 
efficacy of curcumin. Here we have shown that although 
liposomal curcumin can provide some protective efficacy 
against CCl
4
-mediated acute liver damage, better protec-
tion could be obtained through polymeric nanoparticulated 
delivery of curcumin. It was also found that nanoparticulated 
formulation could prevent both lethal oxidative stress as well 
as extensive mitochondrial damage. Additionally, protection 
against apoptotic and necrotic cellular damage and hepato-
cyte cellular architectural disruption was best observed in 
the PLGA nanoparticle-treated rats.
Materials and methods
Materials
Bovine serum albumin (BSA), cholesterol, curcumin, dicetyl 
phosphate (DCP), 2,6-dichloroindophenol (DCIP), didode-
cyldimethylammonium bromide (DMAB), phosphatidyle-
thanolamine (PE), poly(d,l-lactide-co-glycolide) (PLGA) 
(Resomer RG 85:15H), phenazine methosulfate (PMS), and 
succinic acid were purchased from Sigma-Aldrich (St Louis, 
MO, USA). CM-H
2
DCFDA was obtained from Thermo 
Fisher Scientific (Waltham, MA, USA). Ethyl acetate (AR 
grade) was procured from Rankem Fine Chemicals (New 
Delhi, India). Chloroform and methanol were purchased 
from E Merck (Darmstadt, Germany). All other reagents 
were of analytical grade.
animals
Adult female Swiss albino rats (with body weight of 
~150 g), used for this study, were kept at laboratory condi-
tions (26°C–28°C, 60%–80% relative humidity, and 12 hours 
light/dark cycle) for 7 days prior to the start of treatment and 
provided with adequate food and drinking water. The study 
was approved by and carried out under the guidelines of the 
Animal Ethics Committee, India (registration number 147/99/
CPC SEA, India). The experiments were performed accord-
ing to the guidelines of “Principles of Laboratory Animal 
Care” (NIH publication number 85-23, 1985).
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Preparation of curcumin-loaded 
liposomes
Liposomes were prepared according to Gregoriadis and 
Ryman’s method14 by solvent evaporation method. In brief, 
PE, cholesterol, DCP, and curcumin (molar ratio 7:1:1:1) 
were dissolved in chloroform and methanol mixture (2:1, v/v) 
in a round-bottom flask. A thin film was prepared by evapo-
rating the organic solvent mixture, and the film was desic-
cated overnight for complete removal of the solvents. Next 
day, the film was suspended in phosphate-buffered saline 
(PBS, pH 7.2) and sonicated for 30 seconds in a probe-type 
sonicator. To separate the liposome from the unencapsulated 
curcumin, the suspension was ultracentrifuged for 1 hour at 
105,000× g (Sorvall WX Ultra 90; Rotor T-890, Thermo 
Fisher Scientific). To ensure the complete removal of unen-
trapped drug, the pellet was washed thoroughly with PBS 
and finally resuspended in 2 mL PBS.
Preparation of curcumin-loaded 
nanoparticles
Curcumin-encapsulated nanoparticles were prepared by a 
modified emulsion–diffusion evaporation method.15 In short, 
71 mg PLGA and 5 mg curcumin were dissolved in 5 and 
1 mL ethyl acetate, respectively. Then, both the solutions were 
mixed and added dropwise to an aqueous phase containing 
1% DMAB. The oil–water emulsion was stirred for 3 hours at 
room temperature, followed by homogenization for 5 minutes 
at 15,000 rpm (high-speed homogenizer; Polytron PT4000; 
Polytron Kinematica, Lucerne, Switzerland). To remove the 
organic solvent completely, the homogenized solution was 
stirred in a water bath at 40°C for 2 hours. Nanoparticles were 
separated by ultracentrifugation (Sorvall WX Ultra 90; Rotor 
T-890, Thermo Fisher Scientific) at 105,000× g for 1 hour. 
To completely remove the unentrapped curcumin from the 
nanoparticulated formulation, the pellet was washed twice 
with PBS and finally resuspended in 2 mL of PBS.16
characterization of curcumin-loaded 
liposomes and nanoparticles
Entrapment efficiency and in vitro release kinetics 
study
The entrapment efficiency of both the formulations was 
measured by spectrophotometry (Rayleigh, UV-2601 
spectrophotometer; Beijing Beifen-Ruili Analytical 
Instrument (Group) Co., Ltd., Beijing, People's Republic 
of China). The pellet of the liposomal solution obtained 
through ultracentrifugation was dissolved in 2 mL methanol 
overnight at 4°C. The same procedure was also followed 
for nanoparticles, where ethyl acetate was used instead of 
methanol. Finally, the amount of curcumin was measured at 
450 nm by using a standard curve. The percentage of drug 
entrapped was calculated by the following formula: 
 
 
Entrapment
efficiency (%)
Total amount of curcumin
in the p
=
ellet 
Initial amount of curcumin taken
×100
 
In vitro drug release study of curcumin from liposomes 
and nanoparticles was performed by direct dispersion method 
at 37°C and pH 7.4.17,18 In brief, a known quantity of both 
curcumin-loaded liposomes and nanoparticles were taken in 
45 mL of 10 mM PBS and each was divided into 45 micro-
centrifuge tubes (15 sets, each having three tubes). Then 
the tubes were kept at 37°C±0.5°C under constant stirring 
at 50 rpm. At different time intervals, one set of tubes were 
taken out, centrifuged at 105,000× g for 1 hour. Both the 
released and entrapped curcumin were measured at 450 nm, 
and a time versus cumulative drug release curve was plotted 
to understand the release kinetics of curcumin.
Morphological features of curcumin-loaded 
liposomes and nanoparticles
The size and morphological features of curcumin-loaded 
liposomal and nanoparticulated formulations were ana-
lyzed using an atomic force microscopic system (Pico plus 
5500 AFM; Agilent Technologies, Santa Clara, CA, USA). 
In brief, samples were deposited onto a mica sheet, dried 
for 30 minutes, and then scanned by microfabricated silicon 
cantilevers. Images were processed using Pico view 1.10.1 
software (Agilent Technologies). The histogram indicated 
the height of the sample from the mica sheet.19
Pharmacokinetics study of free curcumin, curcumin-
loaded liposomes, and nanoparticles
Eighteen female Swiss albino rats were divided in three 
groups, with each group containing six animals. Two groups 
of rats received free curcumin (8.98 µmol curcumin dissolved 
in 0.5 mL aqueous suspension containing 0.2% dimethyl 
sulfoxide (DMSO) or 22 mg/kg body weight) and nanopar-
ticulated curcumin (0.5 mL suspension contains 8.98 µmol 
curcumin or 22 mg/kg body weight) orally. The rats in the 
third group were administered liposomal curcumin intrave-
nously through tail vein at the same dose (0.5 mL suspension 
contains 8.98 µmol curcumin or 22 mg/kg body weight). They 
were fasted overnight before dosing. Animals had access to 
food and water only after 4 hours of drug administration. 
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Blood was collected into heparinized tubes by retro-orbital 
puncture at 15 and 30 minutes and 1, 2, 4, 10, 20, 25, and 30 
hours after administration of curcumin. Plasma was isolated 
from blood by centrifugation and stored at -20°C prior to high 
performance liquid chromatography (HPLC) analysis.20
HPLC was performed using an XBridge™ C
18
 column 
(4.6×250 mm, 5 µm particle size, Waters, Milford, MA, 
USA) with a mobile phase composed of acetonotrile-5% 
acetic acid (75:25 v/v) at a flow rate of 1.0 mL/min. The 
wavelength for detection was 450 nm, injection volume was 
50 µL, and analysis time was 10 min/sample.
The calculations were done using the Kinetic software 
(Kinetica 5.0, Thermo Fisher Scientific). The area under the 
curve (AUC) was calculated using the trapezoidal method.
stability of the curcumin-loaded liposomes and 
nanoparticles
Stability of curcumin-loaded liposomes and nanoparticles 
were studied according to change in their encapsulation effi-
ciency at two different temperatures, 37°C and 4°C. In short, 
known amounts of each the formulation were taken in 36 mL 
of 10 mM PBS. They were divided into 36 microcentrifuge 
tubes (two sets each with 18 tubes). These two sets were 
incubated at two different temperatures (37°C and 4°C). At 
predetermined time points (0, 1, 2, 7, 14, and 21 days), three 
tubes were taken out from both the temperatures for both the 
formulations and encapsulation efficacies were calculated as 
already described. Then, time versus encapsulation efficacy 
was plotted to determine the stability of the formulations.21
Induction of hepatotoxicity
Hepatotoxicity was induced in all the rats (except the normal 
control group) through a single subcutaneous (SC) injection 
of CCl
4
 (40% v/v in olive oil, 1 mL/kg body weight). Normal 
control animals were injected with a single dose of olive oil 
(1 mL/kg body weight). Free curcumin (8.98 µmol curcumin 
dissolved in 0.5 mL aqueous suspension containing 0.2% 
DMSO), empty and curcumin-loaded nanoparticles (0.5 mL 
suspension contains 8.98 µmol curcumin) were administered 
orally, while empty and curcumin-loaded liposomes (0.5 mL 
suspension contains 8.98 µmol curcumin) were injected into 
the tail vein 2 hours prior to CCl
4
 administration.
After 24 hours of CCl
4
 administration, animals were 
sacrificed, and blood and liver were collected.22 Serum was 
isolated from the blood, and different liver toxicity marker 
enzymes (serum aspartate transaminase [AST], alkaline phos-
phatise [AP], and serum alanine transaminase [ALT]) were 
measured using SGOT(ASAT) Kit (Reitman & Frankel's 
method); Alkaline Phosphatase Kit (Mod. Kind and King's 
method); SGPT(ALAT) Kit (Reitman and Frankel’s method) 
(Coral Clinical Systems, Goa, India).19 The liver was divided 
into two parts: one was fixed in 10% formalin solution for 
histopathological analysis, while the other part was utilized 
for preparation of mitochondrial and cytosolic extract.23
Preparation of mitochondria and 
submitochondrial particles
Conventional differential centrifugation method was chosen 
for isolation of liver mitochondria and submitochondrial 
particles according to the method of Navarro and Boveris.24 
All the biochemical studies were performed within 5 hours 
of mitochondrial isolation.
Preparation of cytosolic fraction
The cytosolic fraction from the liver was prepared by 
homogenizing the organ in 0.25 M sucrose solution, fol-
lowed by two-step centrifugation at 8,200× g and 105,000× g, 
respectively.25
Biochemical analysis and enzymatic 
studies
Mitochondrial rOs level
ROS level in mitochondrial fraction was analyzed spectrofluri-
metrically (LS 3B, PerkinElmer, Waltham, MA, USA) using a 
cell permeable probe, CM-H
2
DCFDA [5-(and-6)-chloromethyl-
2′,7′-dichlorodihydro-fluorescein diacetate acetyl ester].26 The 
values obtained in experimental groups were compared with 
the normal group, considering normal as 100%.
Mitochondrial lipid peroxidation
The conjugated diene/lipohydroperoxide formed in the mem-
brane reflects lipid peroxidation level. First, the mitochon-
drial membrane was extracted with chloroform–methanol 
(2:1, v/v) mixture, and then the lipohydroperoxide level was 
evaluated according to the method of Mandal et al.27
Mitochondrial membrane fluidity
Mitochondrial membrane fluidity was studied spectrofluri-
metrically by measuring the intensity of the fluorescence 
probe diphenyl hexatriene (DPH) both in parallel (I
II
) and 
perpendicular (I⊥) directions of the polarization of the excited 
light. Microviscosity (r) was calculated using the equation, 
r = (I
II 
- I⊥)/(III + 2I⊥).28
succinate dehydrogenase (sDh) and nicotinamide 
adenine dinucleotide (NaDh) oxidase activity
SDH and NADH oxidase activities were evaluated from 
liver submitochondrial particles. In brief, PMS-mediated 
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reduction of DCIP at different time points was measured 
to estimate SDH activity according to Reddy and Weber’s 
method.29 NADH oxidase activity depends on the oxidation 
of NADH at 340 nm.30
reduced glutathione (gsh) and other cellular 
antioxidants status estimation
Reduced glutathione level in cytosolic fraction was deter-
mined spectrophotometrically following the method of 
Davila et al.31 Superoxide dismutase (SOD) (EC 1.15.1.1) 
was assessed by detecting pyrogallol autoxidation according 
to Marklund and Marklund’s method.32 Catalase activity was 
determined by H
2
O
2
 consumption rate, and enzyme activity 
was expressed as the amount of H
2
O
2
 reduced/min/mg 
of protein.33 By measuring the rate of NADH oxidation 
spectrophotometrically at 340 nm, glutathione reductase 
(GR) was assayed.34 Glutathione-S-transferase (GST) and 
glutathione-6-phosphate dehydrogenase (G6PDH) activi-
ties were measured according to the methods of Maiti and 
Chatterjee35 and Ghosh et al,25 respectively.
Western blot analysis of i-NOs, caspase 3, caspase 9, 
and ParP
For immunoblotting analysis, the cytosolic fraction contain-
ing protease and phosphatidase inhibitor was first prepared, 
followed by sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE). The proteins were transferred 
(15 V, 20 minutes) to a polyvinylidene fluoride membrane 
using semidry transfer apparatus (Transblot, Bio-Rad Labo-
ratories Inc., Hercules, CA, USA). After blocking with 4% 
BSA overnight, the membranes were incubated with primary 
inducible nitric oxide synthase (i-NOS), caspase 3, caspase 
9, and PARP antibodies. Alkaline phosphatase-conjugated 
secondary antibody was used. Bands were visualized by using 
Sigma premixed 5-bromo-4-chloro-3-indolyl-phoshate/nitro-
blue tetrazolium substrate solution.
statistical analysis
All the results were expressed as mean ± standard devia-
tion (SD) for five replicates. The significance of differences 
between mean values was calculated by Student’s t-test 
using GraphPad Prism 5 (GraphPad Software, Inc., La Jolla, 
CA, USA), and it was considered significant only when 
P,0.05.
Results
characterization of nanoparticles
The physicochemical characteristics of a formulation deter-
mine the efficacy of the drug delivery vehicle. Investigation 
of the size and surface morphology of curcumin-loaded 
liposomes and nanoparticles by AFM revealed that the lipo-
somes are much larger in size (140±60 nm) in comparison 
to the nanoparticulated formulation of curcumin (35±9 nm; 
Figure 1 and Table 1). Both the particles were spherical in 
shape. The morphology was intact, no cracks and pores were 
observed, and no significant aggregation was noticed. The 
nanoparticles showed narrower size distribution in com-
parison to liposomes. The topological analysis showed that 
the heights of liposomes were more (4 nm) than that of the 
nanoparticles (2 nm). The encapsulation of curcumin was 
higher in liposomes (84%±3%) in comparison to nanopar-
ticles (72%±5%; Table 1).
Study of the in vitro drug release kinetics showed a 
burst in the release of approximately 37% of the drug in the 
first 20 hours in the case of nanoparticulated formulation, 
and after that a sustained release pattern was observed. The 
liposomal formulation, on the other hand, showed a steady 
release pattern till 48 hours (Figure 2).
Pharmacokinetics of free, liposomal, and nanoparticilated 
curcumin showed that free curcumin has very low bioavail-
ability in the plasma. Because of the intravenous injection, 
liposomal curcumin showed a high C
max
 value (3.3 µg/mL) 
at an early time point (15 minutes), which decreased signifi-
cantly with time (K
el
: 0.34 hour-1). In comparison, nanopar-
ticulated curcumin has shown a much higher AUC
(0–∞) value, 
with significantly lower K
el
 (0.11 hour-1) and with almost 
four times more bioavailability in comparison to liposomal 
curcumin (Figure 3 and Table 2).
Stability studies have indicated that both the 
formulations degrade at 37°C, whereas at 4°C both are 
stable (Figure 4).
effect of curcumin-loaded liposomes 
and nanoparticles in preventing hepatic 
toxicity
As subcutaneous administration of 40% CCl
4
 at 1 mL/kg 
body weight causes steatosis and fatty deposition in liver, 
the levels of three hepatocellular marker enzymes AP, 
AST, and ALT in serum were evaluated in different groups 
of animals (Table 3). A significant increase in these serum 
enzyme levels was observed in CCl
4
-treated group of rats 
as compared to normal rats. Free curcumin mixture and 
empty delivery vehicles (both liposome and nanoparticles) 
exerted no significant protection against hepatotoxicity. 
A significant protection was observed in the case of 
liposomal curcumin-treated animals, but the lowest 
toxicity was observed in nanoparticulated curcumin-treated 
animals.
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effect of curcumin-loaded liposomes 
and nanoparticles on the generation 
of mitochondrial rOs
CCl
4
 exerts its hepatotoxic effects by increasing the level 
of cellular ROS. The excess ROS generated in the cell 
further affects different subcellular organelles including 
mitochondria. Treatment of rats with CCl
4
 led to almost a 
threefold increase in mitochondrial ROS in comparison to 
the normal controls (Figure 5). Although free drug showed 
little or no protection, liposomal curcumin showed significant 
Figure 1 atomic force microscopic images of (A) curumin-loaded liposomes and (B) Plga-coated curcumin nanoparticles. 
Note: Topography indicates the height of liposomes and nanoparticles from the substratum, mica sheet.
Abbreviation: Plga, poly(d,l-lactide-co-glycolide).
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protection against CCl
4
-induced ROS development. How-
ever, the most promising effect was observed in those rats 
that were treated with nanoparticulated curcumin.
effect of curcumin-loaded liposomes and 
nanoparticles against oxidative damage 
of mitochondria and submitochondrial 
particles
Excess generation of ROS causes extensive mitochondrial 
damage by generating conjugated dienes as a result of lipid 
peroxidation and thereby reducing membrane microviscosity. 
The extent of mitochondrial damage was studied by measuring 
the mitochondrial diene formation (Figure 6), mitochondrial 
membrane microviscosity, and SDH and NADH oxidase 
activities (Table 4). CCl
4
 administration accelerated cellular 
diene formation in CCl
4
-treated control animals, thereby 
decreasing mitochondrial membrane potential. The free drug 
showed no significant effect in preventing ROS-mediated 
mitochondrial damage. Liposomal curcumin showed a sig-
nificant protective effect by preventing mitochondrial diene 
formation and thereby preserving mitochondrial membrane 
integrity – as evident from mitochondrial membrane viscosity. 
Studies on other mitochondrial marker enzymes like SDH 
and NADH oxidase also proved that liposomal curcumin 
could provide some protection (Table 4). However, the best 
mitochondrial protection could be obtained in rats treated 
with nanoparticulated curcumin.
effect of curcumin-loaded liposomes and 
nanoparticles on antioxidant status of the 
liver
The body has endogenous antioxidants to combat against 
excess ROS intrinsically. But during oxidative stress, the 
depletion of these cellular antioxidants takes place. GSH, 
the most important intracellular antioxidant, showed a 
marked reduction in CCl
4
-treated control animals. Other 
cellular antioxidants like SOD, catalase, G6PDH, GR, and 
GST showed the same trend. Free and liposomal curcumin 
showed no significant protection in preventing the depletion 
of antioxidants. But very promising results were found in the 
rats treated with nanoparticulated curcumin (Table 5).
Pathomorphology of liver section
Pathomorphology of normal rats (Figure 7A) revealed that 
hepatocytes were arranged in cords around hepatic vein form-
ing hepatic lobules. The portal tracts were also normal. The 
liver section of CCl
4
-injected rats showed marked hepatic 
damage, considerable fatty deposition in the cells along 
with partial periportal fibrosis (Figure 7B), massive portal 
inflammation, and centrizonal necrosis (Figure 7C). Similar 
tissue damage, including fibrosis and steatosis, was also 
evident in free curcumin-treated animals (Figure 7D and E). 
Treatment with liposomal curcumin led to commendable 
prevention of the damage, although some cells with fat 
deposition along with deformed cellular architecture were 
still observed in the histopathological analysis (Figure 7F). 
Liver sections from animals treated with nanoparticulated 
Table 1 Entrapment efficacy and mean particle size of curcumin-
loaded liposomes and nanoparticles
Sample name % encapsulation Mean particle 
size (nm)
curcumin-encapsulated  
liposome
84±3 140±60
curcumin-encapsulated  
nanoparticle
72±5 35±9*
Notes: results are expressed as mean ± sD. Mean particle size of curcumin-
encapsulated nanoparticles was compared with liposomal curcumin and showed 
significant difference (*P,0.01).
Abbreviation: sD, standard deviation.
Figure 2 In vitro release kinetics profile of liposomal and nanoparticulated 
curcumin.
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curcumin demonstrated the most efficient prevention against 
CCl
4 
administration, with cellular morphology almost com-
parable to normal rats.
Nitric oxide synthase 2 and intrinsic 
caspase pathway markers immunoblotting
Nitric oxide synthase 2, i-NOS, is one of the key markers 
of free-radical-mediated cellular damage. Administration 
of CCl
4 
increased the expression of i-NOS approximately 
sixfold (Figure 8). While free and liposomal curcumin could 
prevent this stress to a certain extent, nanoparticulated cur-
cumin showed a significant reduction (P,0.001) in i-NOS-
mediated cellular damage.
Mitochondrial damage triggered the intrinsic apoptotic 
pathway, which was evident from the upregulation of 
caspase 3 cleavage, elevated levels of cleaved caspase 9, and 
poly(ADP-ribose) polymerase (PARP) in CCl
4
-administered 
animals (Figure 8). Although liposomal curcumin showed 
some effect in preventing this apoptosis-mediated damage, 
the best protection was observed in nanoparticulated 
curcumin-treated tissue samples, where 2.5-fold lesser 
cleavage of caspase 3 took place. By preventing the cleavage 
of caspase 3, it also prevented further breakage of caspase 9 
and PARP-1, which was reflected in the effect of nanoparticu-
lated curcumin in preventing DNA damage and apoptosis.
Discussion
CCl
4
 is an effective hepatotoxic agent, and even a single 
exposure can promote severe liver toxicity, including necro-
sis and steatosis. Hence, CCl
4
 is widely used as a model for 
evaluating the hepatoprotective activity of new drugs or 
drug formulations.36,37 Our study suggested an enhancement 
of the efficacy of a traditional antioxidant, curcumin, when 
formulated with two delivery devices, liposome and nanopar-
ticle. Both liposomal as well as nanoparticulated curcumin 
have shown better competence in scavenging cellular ROS, 
maintaining cellular antioxidant enzyme levels, preventing 
mitochondrial damage and intrinsic apoptotic pathway, and 
averting i-NOS overexpression. Further evidence suggested 
the nanoparticulated formulation of curcumin to be more 
effective than free and liposomal curcumin in preventing 
CCl
4
-mediated liver damage.
Oxidative stress is a principal aspect of hepatic damage. 
Our group has previously demonstrated that galactose-
grafted liposome encapsulating an antioxidant can provide 
significant protection against CCl
4
-mediated fatty liver 
damage or steatosis.28 We have taken this study forward 
and compared the protective efficacy of curcumin-loaded 
polymeric nanoparticles with curcumin-loaded liposomes. 
Liposomes have several disadvantages for oral delivery as 
the lipid bilayer cannot withstand the harsh conditions in 
the GI tract. Since polymeric nanoparticles can be absorbed 
efficiently through the GI tract, the noninvasive oral delivery 
of polymeric nanoparticles is more advisable. Keeping our 
aim to deliver both the formulations through their best pos-
sible routes in this study, we delivered the curcumin-loaded 
Table 2 Pharmacokinetics parameters of free curcumin and curcumin-loaded liposomes and nanoparticles
Route of administration Free curcumin Liposomal curcumin Nanoparticulated curcumin
Oral Intravenous Oral
Dose (mg/kg b wt) 22 22 22
Cmax (µg/ml) 0.24±0.03 3.30±0.38 1.69±0.22
Tmax (h) 2 0.25 2
Kel (h
-1) 0.20 0.34 0.11
aUc0–∞ (µg/ml/min) 97.5 647.32 2,025.59
Frel (with respect to free curcumin) – 6.64 20.77
Frel (with respect to liposomal curcumin) – – 3.13
Note: Data for Cmax are represented as mean ± sD (n=6).
Abbreviations: Cmax, maximum concentration; Tmax, time at Cmax; Kel, elimination rate constant; aUc, area under the curve; Frel, relative bioavailability; b wt, body weight.
Figure 4 stability study of curcumin-loaded liposomal and nanoparticulated 
formulations at 4°c and 37°c.
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Table 3 effect of curcumin-loaded liposomes and nanoparticles on hepatic toxicity in ccl4-induced hepatic damage
Groups Alkaline phosphatase (KA units) Serum AST (IU/L) Serum ALT (IU/L)
Normal 34.5±1.9 112.5±6.3 37.8±3.6
ccl4 treated (a) 89.8±2.3** 247.1±7.9** 116.7±3.5**
a + empty liposome treated 79.8±4.3 242.83±7.5 111.5±4.3
a + empty nanocapsule treated 78.2±3.6 239.3±8.5 109.2±2.0
a + free cur treated 67.9±2.01## 205.8±5.8## 87.5±4.6#
a + liposomal cur treated 59.9±2.2## 176.1±7.9## 59.5±7.2##
a + nanocapsulated cur treated 48.3±1.2## 131.4±7.5## 48.5±3.7##
Notes: results of each group were expressed as mean ± SD of five animals. CCl4-treated controls were compared with normal animals (**P,0.001) and other experimental 
groups showed significant difference (##P,0.001 and #P,0.01) from the ccl4-treated control group (a).
Abbreviations: asT, aspartate transaminase; alT, alanine transaminase; sD, standard deviation.
Figure 5 Values of rOs in liver mitochondria of rats.
Note: ccl4-treated controls were compared with normal animals (***P,0.0001) and other experimental groups showed significant difference (
###P,0.0001 and ##P,0.001) 
from the ccl4-treated control group (a).
Abbreviation: rOs, reactive oxygen species.
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liposomes intravenously and nanoparticulated formulation 
orally.
Curcumin has various biological activities. It has 
been reported to have antioxidative, anticarcinogenic, 
anti-inflammatory, and immunomodulatory properties, with 
insignificant toxicity.38–40 A number of medicinal proper-
ties of curcumin have already been reviewed extensively 
in recent years.41,42 But as curcumin is insoluble in water, it 
has very poor GI absorption and thereby low bioavailability. 
Recent studies have shown that drug delivery devices such 
as nanoparticles and liposomes offer a potential opportunity 
to overcome the challenges associated with insoluble drugs 
like curcumin.43 Studies herein have demonstrated that both 
the delivery devices (liposome and nanoparticle) are spheri-
cal in shape with small particle size and higher encapsula-
tion efficiency (Figure 1 and Table 1). The comparatively 
smaller particle size of nanoparticles (35 nm) over liposomes 
(140 nm) helps in better cellular uptake of the nanopar-
ticulated formulation. Moreover, pharmacokinetics studies 
show that nanoparticulated curcumin remains in the system 
for a much longer time than the liposome-loaded curcumin 
(AUC
0–∞ is higher and Kel is lower). Relative bioavailability 
of nanoparticulated formulation is almost four times higher 
than liposomal formulation (Figure 3 and Table 2). Also, 
the initial burst release of the nanoparticulated curcumin as 
compared to a steady release from liposome (Figure 2) may 
provide an added advantage to the nanoparticulated formula-
tion to combat the CCl
4
-mediated cellular damage.
CCl
4 
exerts its hepatotoxic effect through extensive ROS 
production. CCl
4
 is biotransformed by hepatic microsomal 
cytochrome P450 to produce toxic metabolites, trichlo-
romethyl (CCl
3
*) and trichloromethyl peroxy (CCl
3
OO*) 
radicals, which further trigger oxidative stress, cellular 
inflammation, and massive cellular damage. The mitochon-
drion is the bioenergetic and metabolic center of eukaryotic 
cells.36,44 The mitochondrion is the target as well as the source 
of ROS and peroxynitrite. CCl
3
* and CCl
3
OO* exhibit a 
strong affinity for membrane lipids of the cell and different 
subcellular organelles and generate lipohydroperoxide. The 
extensive formation of ROS and reactive nitrogen species 
within the mitochondria triggers the opening of mitochondrial 
membrane permeability transition pores, decrease of mito-
chondrial membrane fluidity, and collapse of mitochondrial 
membrane potential. This extensive mitochondrial damage is 
the critical step in liver injury.45,46 Mitochondrial outer mem-
brane permeabilization leads to the release of mitochondrial 
intermembrane protein cytochrome c into the cytosol. In the 
cytosol, cytochrome c binds to Apaf-1 and activates caspase 9, 
which triggers caspase 3-mediated apoptotic pathway.3 Our 
studies have shown that the mitochondrial lipohydroperox-
ide levels that increased significantly due to CCl
4
 admin-
istration were arrested by liposomal and nanoparticulated 
curcumin treatment. However, the best prevention was seen 
in nanoparticulated curcumin-treated animals (Figure 6). 
Prevention of mitochondrial damage was also evident from 
the levels of mitochondrial membrane microviscosity, ie, the 
fluidity of the membrane and mitochondrial marker enzymes, 
NADH oxidase, and SDH activity (Table 4). Because of 
the protection of the mitochondria and their membranes, 
the cytochrome c-mediated intrinsic apoptotic pathway was 
successfully arrested by treatment with nanoparticulated 
curcumin (Figure 8).
Mitochondrial damage by CCl
4
 further triggers exces-
sive production of other cellular ROS like superoxide (O
2
•), 
hydrogen peroxide (H
2
O
2
), and hydroxyl radicals (•OH) 
and causes cellular necrosis.47 Continuous interaction of 
these free radicals with different cellular components like 
protein, lipid, DNA, carbohydrates, and membrane gener-
ates various cellular adducts that cumulatively cause cel-
lular damage. The prime function of antioxidative defense 
Table 4 effect of curcumin-loaded liposomes and nanoparticles on rOs, NaDh oxidase, and sDh levels in rat liver mitochondria
Groups Membrane microviscosity  
([r°/r -1]-1)
NADH oxidase level (nmol  
of oxidized NADH/min/mg pr)
SDH activity (µL DCIP 
reduced/min/mg pr)
Normal 0.645±0.051 5.74±0.19 0.69±0.02
ccl4 treated (a) 0.337±0.059*** 7.17±0.76** 0.24±0.02***
a + empty liposome treated 0.329±0.067 7.09±0.69 0.24±0.02
a + empty nanocapsule treated 0.347±0.021 7.09±0.31 0.33±0.05
a + free cur treated 0.422±0.076 6.89±0.52 0.30±0.02
a + liposomal cur treated 0.497±0.065## 6.74±0.19 0.45±0.06###
a + nanocapsule cur treated 0.605±0.037### 5.92±0.32## 0.62±0.05###
Notes: results of each group were expressed as mean ± SD of five animals. CCl4-treated controls were compared with normal animals (***P,0.0001, **P,0.001) and other 
experimental groups showed significant difference (###P,0.0001 and ##P,0.001) from the ccl4-treated control group (a).
Abbreviations: rOs, reactive oxygen species; NaDh, nicotinamide adenine dinucleotide; sDh, succinate dehydrogenase; DcIP, 2,6-dichloroindophenol; sD, standard 
deviation; pr, protein.
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systems is suppression of generation of ROS, scavenging of 
ROS, clearance by neutralization, repairing and reconstitu-
tion of damage, and induction of antioxidant proteins and 
enzymes.48 Reduced glutathione (GSH) plays a critical role 
of coenzyme and participates in the removal of free radicals 
and peroxides, maintains membrane thiols, and also acts as 
a substrate for different antioxidant marker enzymes like 
glutathione peroxidase (GPx), GR, and GST.49 SOD, CAT, 
and GPx mutually constitute a supportive enzyme system 
of the first line of cellular defense against reactive oxidants 
by decomposing O
2
• and H
2
O
2
 to prevent the formation of 
more harmful hydroxyl and alkoxyl radicals.50 The decrease 
of all these antioxidant enzyme levels (Table 5) was due to 
extensive oxidative stress and higher ROS level (Figure 5) 
in the cellular system. Both liposomal and nanoparticulated 
curcumin have shown promising results against this oxidative 
stress by preventing the increase in ROS and maintaining 
cellular antioxidants balance.
Nitric oxide (NO) plays a crucial role as a vasodilator, 
neurotransmitter, and an antimicrobial agent in the normal 
body system.51 However, the role of NO in hepatic dam-
age remains controversial. Although some studies have 
shown that NO protects against CCl
4
-induced liver injury, 
a good number of studies have also shown excessive NO 
production by i-NOS causing extensive hepatocellular 
damage.52–55 The latter hypothesis supported our results 
in which i-NOS expression increased significantly in liver 
homogenate of CCl
4
-intoxicated group, which could be pre-
vented by the administration of nanoparticulated curcumin 
(Figure 8).
Portal inflammation and centrizonal necrosis are other 
most common effect of liver damage by CCl
4
. Hepatocytes 
comprise almost 70%–80% of the liver mass and include 
different cells like endothelial cells, stellate(Ito) cells, and 
mainly, Kupffer cells. Kupffer cells are the hot spot of 
hepatic inflammation as they are mainly involved in anti-
gen presentation and clearance of particulates from portal 
circulation. Initial tissue damage and focal tissue necrosis 
release proinflammatory cytokine, tumor necrosis factor-α, 
and interleukin-1, which may induce apoptosis or initiate 
inflammatory processes, leading to extensive liver damage.56 
Histopathological studies have shown that CCl
4
 administration 
extensively damages the liver cellular architecture, leading 
to centrizonal necrosis, portal fibrosis, and marked steatosis. 
This damage was prevented by liposomal and nanoparticu-
lated curcumin administration. However, the best protection 
was observed with curcumin nanoparticles (Figure 7). The 
downregulation of liver toxicity marker enzymes (namely, T
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Figure 7 hematoxylin–eosin-stained liver section of normal and experimental rats.
Notes: (A) Olive oil-treated control (100×) showing normal liver architecture. ccl4-treated control animals showing partial portal fibrosis () (B) (100×) and a significant 
number of fat-deposited cells () along with portal inflammation and centrizonal necrosis () (C) (100×). (D) ccl4 + free cur-treated animals (100×) showing some 
deformed cellular architecture with a large number of fatty acid-deposited cells, which is much clear with a higher magnification (400×) (E). ccl4 + lipo cur treated (F) (100×) 
also showing some fat-deposited cells. (G) ccl4 + nano cur treated (100×), showing architecture similar to normal.
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Vesiculated (liposomal and nanoparticulated) curcumin in hepatocellular damage
Figure 8 Western blot showing expression of inflammatory modulator (i-NOS) and different intrinsic apoptotic pathway markers.
Notes: Fold changes of expression (measured by ImageJ software) have been shown along with the blot. control group (ccl4 treated) was compared with normal, and the 
value was significantly different where **P,0.001, ***P,0.0001, ##P,0.001, and ###P,0.0001 are significantly different from the CCl4-treated control group (a).
Abbreviation: i-NOs, inducible nitric oxide synthase.
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AP, AST, and ALT) proved that a genuine protection can be 
provided by this nanoparticulated formulation (Table 3).
Conclusion
The results obtained strongly demonstrate the efficacy of 
nanoparticulated curcumin in preventing CCl
4
-mediated 
fatty liver damage or steatosis. Curcumin possesses excellent 
antioxidative and anti-inflammatory properties; however, 
because of low oral bioavailability, curcumin is not an 
effective drug against liver damage. Both liposomal as well 
as nanoparticulated formulations can increase the efficacy 
of curcumin many fold. However because of its small size, 
better cellular absorption, and longer persistence in the 
circulating system, curcumin-loaded nanoparticles can be 
considered as a promising therapeutic strategy against liver 
toxicity.
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